{"version":"1.0","provider_name":"Pharma Trend","provider_url":"https:\/\/pharma-trend.com\/en","author_name":"Business Wire","author_url":"https:\/\/pharma-trend.com\/en\/author\/business\/","title":"Cybin Announces Results of Shareholders\u2019 Meeting - Pharma Trend","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"00EoeWSEhl\"><a href=\"https:\/\/pharma-trend.com\/en\/cybin-announces-results-of-shareholders-meeting\/\">Cybin Announces Results of Shareholders\u2019 Meeting<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/pharma-trend.com\/en\/cybin-announces-results-of-shareholders-meeting\/embed\/#?secret=00EoeWSEhl\" width=\"600\" height=\"338\" title=\"&#8220;Cybin Announces Results of Shareholders\u2019 Meeting&#8221; &#8212; Pharma Trend\" data-secret=\"00EoeWSEhl\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/pharma-trend.com\/en\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","description":"TORONTO&#8211;(BUSINESS WIRE)&#8211;Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (\u201cCybin\u201d or the \u201cCompany\u201d), a biopharmaceutical company focused on progressing \u201cPsychedelics to TherapeuticsTM\u201d, is pleased to announce the voting results for each of the matters presented at the Company\u2019s annual meeting of shareholders held on August 15, 2022 (the \u201cMeeting\u201d). There were 71 shareholders represented in person or by ... [Read more...]","thumbnail_url":"https:\/\/mms.businesswire.com\/media\/20220815005677\/en\/1084589\/21\/Cybin_Primary_Logo_Blue_Final.jpg"}